Current News

Contact | Print version | PDF version | Send article | RSS feed

Eden Biodesign and Stealthyx Therapeutics sign deal to develop enhanced treatment for rheumatoid arthritis

10 Mar 2008 - Eden Biodesign Ltd and Stealthyx Therapeutics Ltd, a London based biotechnology company, announced that they have entered into an agreement to develop and produce Stealthyx's lead therapeutic candidate that the company is evaluating for treatment of a range of inflammatory diseases including rheumatoid arthritis.
 
The product will incorporate Stealthyx Therapeutics' proprietary Prothyx technology that has been developed by Professor Yuti Chernajovsky at St. Bartholomews Hospital and The London, Queen Mary's School of Medicine and Dentistry, University of London. Prothyx harnesses the properties of a naturally occurring peptide to confer stability and disease targeting biological therapeutics resulting in improved efficacy and lower side effect profile.
 
This project has been funded by the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA).